NCT05272384 2026-03-18Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaNational Cancer Institute (NCI)Phase 1 Recruiting32 enrolled
NCT03038672 2025-11-10Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasNational Cancer Institute (NCI)Phase 2 Active not recruiting54 enrolled 12 charts